Eutropics’ PraediCare Dx™ provides prognostic and predictive information gained from an understanding of cancer cell survival mechanisms.
Eutropics’ proprietary platform integrates a fundamental principle of cancer cell biology in a way that provides assays that are more accurate than existing companion diagnostic tests. Most current diagnostic tests rely on static measurements of factors that are involved in this process, including genetic abnormalities and protein abundance or modification. Praedicare Dx™ goes one step beyond and provides a functional read-out of several of the terminal steps in the process of drug response in the cancer cell. The data collected from such measurements along with clinical variables feed proprietary algorithms that provide predictive information. Eutropics’ platform provides a more accurate way to guide the use of existing and experimental therapies.
Advantages of PraedicareDx over other methods: Using a proprietary approach Praedicare DxTM interrogates responsiveness of patient tumor cells that are viably frozen at time of biopsy and tested immediately upon thawing, or tested very soon after biopsy. The readout provides a powerful surrogate biomarker that correlates to patient response to treatment.